Skip to main content
LexaGene Holdings Inc. logo

LexaGene Holdings Inc. — Investor Relations & Filings

Ticker · LXG.H ISIN · CA52886L1031 LEI · 529900GAYVSL5JI2WX16 TSXV Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2023-02-28 Regulatory Filings
Country CA Canada
Listing TSXV LXG.H

About LexaGene Holdings Inc.

https://www.lexagene.com

LexaGene Holdings Inc. was a biotechnology company specializing in the research, development, and commercialization of molecular diagnostic systems for rapid, on-site pathogen detection. The company pioneered the MiQLab System, a fully-automated, open-access platform designed to detect biological contaminants and pathogens. This technology aimed to significantly reduce analysis time, often cutting detection periods from days to approximately one hour. LexaGene filed for Chapter 7 bankruptcy in February 2023.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that LexaGene Holdings, Inc. has filed for Chapter 7 bankruptcy and ceased operations. It discusses the bankruptcy filing, liquidation proceedings, and the impact on shareholders and creditors. There are no financial statements, detailed financial performance data, or management analysis of financial results. The document is an announcement of a significant corporate event (bankruptcy filing) rather than a financial report, earnings release, or regulatory filing with detailed financial data. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is also not a delisting announcement since the company states it does not intend to seek voluntary delisting. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the bankruptcy filing and related corporate status update, which does not fit into more specific categories.
2023-02-28 English
Material change report - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by LexaGene Holdings Inc. It announces the results of the company's Annual General Meeting (AGM) held on February 8, 2023, including re-election of directors, auditor re-appointment, amendments to the Omnibus Incentive Plan, and approval of executive compensation. The document is a regulatory filing reporting material changes and AGM results, not the AGM presentation materials themselves. It is not a full annual report or financial statement but a formal announcement of material changes related to the AGM. The document length is 9360 characters, which is substantial but the content is focused on reporting AGM outcomes and related corporate governance changes. Therefore, the best fitting category is Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-02-10 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release announcing the results of the Annual General Meeting (AGM) held on February 8, 2023. It details shareholder votes on director re-elections, auditor re-appointment, amendments to the Omnibus Incentive Plan, and advisory approval of executive compensation. It also mentions the Board's confirmation of executive officer appointments following the AGM. The content focuses on the outcomes and resolutions passed at the AGM rather than providing the full AGM materials or management circular itself. The document length is 8304 characters, which is consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results from the AGM.
2023-02-10 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 51-102F3 Material Change Report filed by LexaGene Holdings Inc. It announces a material change related to the company's MiQLab System detecting Mycoplasma at minute levels, with details about the feasibility study and customer interest. The form and content indicate it is a regulatory announcement of a material change rather than a full financial report or earnings release. It is not an annual or interim report, audit report, or earnings release. It is a specific regulatory filing reporting a material change event as required by securities regulations. Therefore, the document fits best under Regulatory Filings (RNS). The document length (8638 characters) and detailed content confirm it is not a brief announcement or certification but a substantive regulatory filing.
2023-01-18 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a technical achievement related to the sensitivity of LexaGene's MiQLab System for detecting Mycoplasma, which is of interest to biopharma customers. It discusses product development milestones, feasibility study results, and future steps with customers. There are no financial statements, regulatory filings, or detailed financial data presented. The document is promotional and informative about product capabilities and business progress rather than a formal financial or regulatory report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about product development and customer interest, which aligns best with a Regulatory Filings (RNS) classification as a general regulatory announcement or corporate news release that does not fit other specific categories.
2023-01-18 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes details about the Annual General Meeting, such as the date, location, and agenda items including election of directors, appointment of auditors, approval of incentive plans, and executive compensation. It explicitly states it is a proxy statement and not the annual report or financial statements themselves. The document is a solicitation of shareholder votes and provides information for voting, which aligns with the definition of Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters, but it contains substantive proxy materials rather than just an announcement. Therefore, the correct classification is PSI.
2022-12-30 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.